Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Biogen and AGTC join forces to develop gene therapies in ophthalmology Biogen (BIIB) and AGTC have established collaboration and license agreement to develop gene-based therapies for multiple ophthalmic diseases.
Drug Research > Drug Discovery & Development > News
Kite Pharma join forces with Leukemia & Lymphoma Society Kite Pharma and the Leukemia & Lymphoma Society (LLS) have entered into a partnership to enhance the development of Kite's lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL).
Drug Research > Drug Discovery & Development > News Spyryx gets development award to advance novel therapy for cystic fibrosis By PBR Staff Writer
US-based biopharmaceutical firm Spyryx Biosciences has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of its therapeutic peptides for cystic fibrosis (CF).
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Taking the Strain
| By Eppendorf
Today, the rapidly expanding demand for vaccine products for viral diseases such as rabies has necessitated the development of more sophisticated production techniques based around cell culture systems. This article reviews vaccine production strategies, with a focus on rabies, looking specifically at the use of the Vero cell line - used worldwide and approved by the US Food and Drug Administration - as well as media technology and the bioreactor options available.
Drug Research > Drug Discovery & Development > White Papers
Spyryx gets development award to advance novel therapy for cystic fibrosis
By PBR Staff Writer
US-based biopharmaceutical firm Spyryx Biosciences has received an award from Cystic Fibrosis Foundation Therapeutics, which will support development of its therapeutic peptides for cystic fibrosis (CF).
Drug Research > Drug Discovery & Development > News
Barda exercises $3m in additional contract funding to develop Aeolus' AEOL 10150 to treat acute radiation syndrome
Aeolus Pharmaceuticals, a biotechnology company developing compounds to protect against radiological and chemical threats in partnership with the US Government, announced that the Biomedical Advanced Research and Development Authority (BARDA) exercised $3m in additional contract options under its advanced research and development contract for AEOL 10150.
Drug Research > Drug Discovery & Development > News
Immunovaccine, Incyte to evaluate new immunotherapy combination to treat platinum-sensitive ovarian cancer
By PBR Staff Writer
Immunovaccine has entered into a non-exclusive clinical trial collaboration with Incyte to evaluate the combination of DPX-Survivac and epacadostat in patients with platinum-sensitive ovarian cancer.
Drug Research > Drug Discovery & Development > News
Aquinox releases positive results from Phase II trial with AQX-1125 to treat BPS/IC
Aquinox Pharmaceuticals (Aquinox) has announced results from its Phase II LEADERSHIP randomized clinical trial investigating the therapeutic potential of AQX-1125 in treating pain in patients with bladder pain syndrome/interstitial cystitis (BPS/IC).
Drug Research > Drug Discovery & Development > News
Vaccinex starts Phase II trial of VX15/2503 antibody to treat Huntington's disease
By PBR Staff Writer
US-based clinical-stage immunotherapy firm Vaccinex has started a Phase II clinical trial (SIGNAL) of anti-semaphorin 4D antibody VX15/2503 (VX15) for the treatment of patients with Huntington's disease (HD).
Drug Research > Drug Discovery & Development > News
ObsEva begins enrollment in Phase II TERM trial of OBE001 in pregnant women with preterm labor
ObsEva, a Swiss biopharmaceutical company developing a novel generation of drugs addressing serious conditions compromising pregnancy from conception to birth, announced the recruitment of the first patient in the TERM study, a Phase II clinical trial in pregnant women with preterm labor of its lead compound OBE001, an orally active oxytocin receptor antagonist.
Drug Research > Drug Discovery & Development > News
Amgen reports positive results from Phase II trial of AMG 334 to prevent migraine
By PBR Staff Writer
Amgen has reported positive interim results from its open-label extension of the global Phase II trial evaluating the safety and efficacy of AMG 334 for the prevention of episodic migraine.
Drug Research > Drug Discovery & Development > News
Epizyme reports positive data from Phase I trial of tazemetostat to treat non-hodgkin lymphoma
Epizyme, a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today reported results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful clinical activity when used as an oral monotherapy in patients with advanced B-cell non-Hodgkin lymphomas (NHL) and solid tumors.
Drug Research > Drug Discovery & Development > News
Akashi reports positive clinical data on HT-100 in DMD patients
Akashi Therapeutics a clinical stage biopharmaceutical company developing treatments for Duchenne muscular dystrophy (DMD), announced positive interim clinical data from an ongoing Phase 1b/2a clinical program with HT-100 (delayed-release halofuginone) an orally available, small molecule developed to reduce fibrosis and inflammation and promote healthy muscle fiber regeneration in boys with DMD.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests